BHC
Price
$7.01
Change
+$0.19 (+2.79%)
Updated
Dec 11 closing price
Capitalization
2.6B
75 days until earnings call
Intraday BUY SELL Signals
ZTS
Price
$118.58
Change
+$0.92 (+0.78%)
Updated
Dec 12, 04:05 PM (EDT)
Capitalization
51.85B
67 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BHC vs ZTS

Header iconBHC vs ZTS Comparison
Open Charts BHC vs ZTSBanner chart's image
Bausch Health Companies
Price$7.01
Change+$0.19 (+2.79%)
Volume$2.04M
Capitalization2.6B
ZOETIS
Price$118.58
Change+$0.92 (+0.78%)
Volume$703
Capitalization51.85B
BHC vs ZTS Comparison Chart in %
View a ticker or compare two or three
VS
BHC vs. ZTS commentary
Dec 13, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BHC is a Hold and ZTS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 13, 2025
Stock price -- (BHC: $7.01 vs. ZTS: $117.66)
Brand notoriety: BHC and ZTS are both notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: BHC: 78% vs. ZTS: 141%
Market capitalization -- BHC: $2.6B vs. ZTS: $51.85B
BHC [@Pharmaceuticals: Generic] is valued at $2.6B. ZTS’s [@Pharmaceuticals: Generic] market capitalization is $51.85B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.29B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BHC’s FA Score shows that 0 FA rating(s) are green whileZTS’s FA Score has 2 green FA rating(s).

  • BHC’s FA Score: 0 green, 5 red.
  • ZTS’s FA Score: 2 green, 3 red.
According to our system of comparison, ZTS is a better buy in the long-term than BHC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BHC’s TA Score shows that 6 TA indicator(s) are bullish while ZTS’s TA Score has 4 bullish TA indicator(s).

  • BHC’s TA Score: 6 bullish, 4 bearish.
  • ZTS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, BHC is a better buy in the short-term than ZTS.

Price Growth

BHC (@Pharmaceuticals: Generic) experienced а -5.01% price change this week, while ZTS (@Pharmaceuticals: Generic) price change was -2.28% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.50%. For the same industry, the average monthly price growth was -1.01%, and the average quarterly price growth was +19.25%.

Reported Earning Dates

BHC is expected to report earnings on Feb 25, 2026.

ZTS is expected to report earnings on Feb 17, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.50% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZTS($51.9B) has a higher market cap than BHC($2.6B). ZTS has higher P/E ratio than BHC: ZTS (19.81) vs BHC (7.23). BHC YTD gains are higher at: -13.027 vs. ZTS (-26.825). ZTS has higher annual earnings (EBITDA): 4.04B vs. BHC (3B). ZTS has less debt than BHC: ZTS (6.79B) vs BHC (21.7B). BHC (9.86B) and ZTS (9.4B) have equivalent revenues.
BHCZTSBHC / ZTS
Capitalization2.6B51.9B5%
EBITDA3B4.04B74%
Gain YTD-13.027-26.82549%
P/E Ratio7.2319.8136%
Revenue9.86B9.4B105%
Total Cash1.73BN/A-
Total Debt21.7B6.79B320%
FUNDAMENTALS RATINGS
BHC vs ZTS: Fundamental Ratings
BHC
ZTS
OUTLOOK RATING
1..100
1454
VALUATION
overvalued / fair valued / undervalued
1..100
37
Fair valued
30
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10025
PRICE GROWTH RATING
1..100
5564
P/E GROWTH RATING
1..100
9889
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ZTS's Valuation (30) in the Pharmaceuticals Generic industry is in the same range as BHC (37) in the Pharmaceuticals Other industry. This means that ZTS’s stock grew similarly to BHC’s over the last 12 months.

ZTS's Profit vs Risk Rating (100) in the Pharmaceuticals Generic industry is in the same range as BHC (100) in the Pharmaceuticals Other industry. This means that ZTS’s stock grew similarly to BHC’s over the last 12 months.

ZTS's SMR Rating (25) in the Pharmaceuticals Generic industry is significantly better than the same rating for BHC (100) in the Pharmaceuticals Other industry. This means that ZTS’s stock grew significantly faster than BHC’s over the last 12 months.

BHC's Price Growth Rating (55) in the Pharmaceuticals Other industry is in the same range as ZTS (64) in the Pharmaceuticals Generic industry. This means that BHC’s stock grew similarly to ZTS’s over the last 12 months.

ZTS's P/E Growth Rating (89) in the Pharmaceuticals Generic industry is in the same range as BHC (98) in the Pharmaceuticals Other industry. This means that ZTS’s stock grew similarly to BHC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BHCZTS
RSI
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 2 days ago
69%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
82%
Bullish Trend 2 days ago
63%
Momentum
ODDS (%)
Bullish Trend 3 days ago
68%
Bearish Trend 2 days ago
65%
MACD
ODDS (%)
Bullish Trend 3 days ago
67%
Bullish Trend 2 days ago
65%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
78%
Bearish Trend 2 days ago
61%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
66%
Bearish Trend 2 days ago
62%
Advances
ODDS (%)
Bullish Trend 9 days ago
73%
Bullish Trend 18 days ago
55%
Declines
ODDS (%)
Bearish Trend 4 days ago
79%
Bearish Trend 4 days ago
59%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
71%
Bearish Trend 2 days ago
54%
Aroon
ODDS (%)
Bullish Trend 3 days ago
74%
Bearish Trend 2 days ago
61%
View a ticker or compare two or three
Interact to see
Advertisement
BHC
Daily Signal:
Gain/Loss:
ZTS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GLNMX25.070.12
+0.48%
MFS Global New Discovery R4
RRRAX21.370.07
+0.33%
DWS RREEF Real Estate Securities A
TRIRX80.81-0.08
-0.10%
Nuveen Large Cap Gr Idx Retire
ATGDX14.16-0.02
-0.14%
American Century International Gr R6
RYMCX8.17-1.08
-11.68%
Royce Micro-Cap Consult

BHC and

Correlation & Price change

A.I.dvisor indicates that over the last year, BHC has been loosely correlated with AMRX. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if BHC jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BHC
1D Price
Change %
BHC100%
+2.79%
AMRX - BHC
38%
Loosely correlated
+0.33%
AMPH - BHC
36%
Loosely correlated
+0.74%
VTRS - BHC
35%
Loosely correlated
-0.09%
HCM - BHC
27%
Poorly correlated
-1.31%
ESPR - BHC
26%
Poorly correlated
+6.53%
More